S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:PTGX

Protagonist Therapeutics (PTGX) Stock Price, News & Analysis

$28.93
+0.45 (+1.58%)
(As of 03/28/2024 ET)
Today's Range
$28.16
$29.27
50-Day Range
$24.33
$32.15
52-Week Range
$13.72
$33.34
Volume
653,354 shs
Average Volume
628,254 shs
Market Capitalization
$1.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

Protagonist Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
24.4% Upside
$36.00 Price Target
Short Interest
Bearish
5.87% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.11mentions of Protagonist Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.94 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $1.18 to ($0.97) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.82 out of 5 stars

Medical Sector

854th out of 939 stocks

Pharmaceutical Preparations Industry

404th out of 444 stocks

PTGX stock logo

About Protagonist Therapeutics Stock (NASDAQ:PTGX)

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX Stock Price History

PTGX Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
PTGX Apr 2024 15.000 call
PTGX Apr 2024 30.000 put
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
PTGX Mar 2024 25.000 call
See More Headlines
Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PTGX
Fax
N/A
Employees
112
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.00
High Stock Price Target
$38.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+24.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-78,960,000.00
Pretax Margin
-131.59%

Debt

Sales & Book Value

Annual Sales
$60 million
Book Value
$5.84 per share

Miscellaneous

Free Float
55,361,000
Market Cap
$1.69 billion
Optionable
Optionable
Beta
2.05
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Dinesh V. Patel Ph.D. (Age 67)
    CEO, President, Secretary & Director
    Comp: $883.46k
  • Dr. Suneel K. Gupta Ph.D. (Age 65)
    Chief Development Officer
    Comp: $640.89k
  • Dr. Mark Smythe Ph.D. (Age 59)
    Founder & VP Technology
  • Mr. Asif Ali (Age 50)
    Executive VP & Chief Financial Officer
  • Mr. Mohammad Masjedizadeh Ph.D.
    Executive VP & Chief Technical Officer
  • Mr. Matthew M. Gosling (Age 53)
    Executive VP & General Counsel
  • Ms. Carena Spivey
    Senior Vice President of Human Resources
  • Dr. Ashok Bhandari Ph.D. (Age 60)
    Executive VP & Chief Drug Discovery and Preclinical Development Officer
  • Dr. Scott Eric Plevy M.D.
    Executive VP & Therapeutic Head of Gastroenterology
  • Mr. Carter J. King (Age 53)
    Executive Vice President of Business Development

PTGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Protagonist Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings
or view top-rated stocks.

What is Protagonist Therapeutics' stock price target for 2024?

4 analysts have issued twelve-month price targets for Protagonist Therapeutics' stock. Their PTGX share price targets range from $32.00 to $38.00. On average, they anticipate the company's share price to reach $36.00 in the next year. This suggests a possible upside of 24.4% from the stock's current price.
View analysts price targets for PTGX
or view top-rated stocks among Wall Street analysts.

How have PTGX shares performed in 2024?

Protagonist Therapeutics' stock was trading at $22.93 at the beginning of the year. Since then, PTGX stock has increased by 26.2% and is now trading at $28.93.
View the best growth stocks for 2024 here
.

When is Protagonist Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PTGX earnings forecast
.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) released its earnings results on Tuesday, February, 27th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.05 by $0.39. The business earned $60 million during the quarter, compared to the consensus estimate of $60 million.

What ETF holds Protagonist Therapeutics' stock?

Invesco Dorsey Wright Healthcare Momentum ETF holds 129,690 shares of PTGX stock, representing 1.50% of its portfolio.

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?

Protagonist Therapeutics (PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (9.22%), Vanguard Group Inc. (5.47%), Vanguard Group Inc. (5.41%), Point72 Asset Management L.P. (4.53%), Kynam Capital Management LP (3.48%) and Price T Rowe Associates Inc. MD (1.43%). Insiders that own company stock include Asif Ali, David Y Liu, Dinesh V Ph D Patel, Suneel Gupta and William D Waddill.
View institutional ownership trends
.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PTGX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners